Sanofi 13F holdings
Sanofi reported 10 positions with a total reported value of $534.0M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-07-28. Top holdings by reported value: MGTX MeiraGTx Holdings plc (30.9%), INBX Inhibrx Biosciences, Inc. (20.5%), NVAX Novavax (12.1%), ANAB AnaptysBio (10.4%), ODTX Odyssey Therapeutics Inc. (7.0%). Against 2026-03-31 it opened 2 new positions and exited 1. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Sanofi files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
10 largest of 10 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| MGTX MeiraGTx Holdings plc | 12,197,737 | $164.8M | 30.9% |
| INBX Inhibrx Biosciences, Inc. | 1,157,926 | $109.7M | 20.5% |
| NVAX Novavax | 6,880,481 | $64.8M | 12.1% |
| ANAB AnaptysBio | 821,917 | $55.5M | 10.4% |
| ODTX Odyssey Therapeutics Inc. | 1,991,918 | $37.3M | 7.0% |
| AGMB Agomab Therapeutics NV | 2,783,096 | $36.1M | 6.8% |
| MPLT MapLight Therapeutics Inc. | 912,041 | $32.7M | 6.1% |
| TRAX First Tracks Biotherapeutics Inc. | 821,917 | $16.5M | 3.1% |
| IMRX Immuneering Corp | 2,708,559 | $13.5M | 2.5% |
| QTTB Q32 Bio Inc. | 244,083 | $3.1M | 0.6% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 2 in all · reported value as of 2026-06-30
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 1 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| ELDN Eledon | 814,980 | $2.5M | 0.7% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
No position was increased.
Decreases
No position was decreased.
CIK 1121404 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
